The acquisition of Deciphera Pharmaceuticals by Ono Pharmaceutical at a premium price of $25.60 per share directly impacts DCPH's stock price in the short term. The announcement of such a significant acquisition typically leads to a positive market reaction for the target company's stock, as the buyout price often represents a premium to the current trading price. The high relevance and importance scores reflect the direct impact of this acquisition on Deciphera Pharmaceuticals, with a high confidence level in the analysis based on the clear terms and significant equity value of the deal.